Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Thrush Clear all

Conditions: Candidiasis
Interventions: Caspofungin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Vulvovaginal Candidiasis
Interventions: Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Candidemia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania • Providence, Rhode Island

Conditions: Candidiasis
Interventions: Anidulafungin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 53
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: Vulvovaginal Candidiasis
Interventions: MGCD290; Drug
Lead sponsor: MethylGene Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more

Conditions: Candidiasis, Invasive, Candidemia
Interventions: SCY-078, Fluconazole, Echinocandin; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Candidiasis
Interventions: Micafungin, Liposomal Amphotericin B; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Not listed
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more

Conditions: Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions: Boric acid, Placebo; Drug · Other
Lead sponsor: pH-D Feminine Health LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 26
States / cities: Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more

Conditions: Candidiasis, Vulvovaginal
Interventions: OCF001 Intravaginal Gel, Placebo Gel; Drug
Lead sponsor: Sano Chemicals Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Candidiasis
Interventions: Fluconazole Powder; Drug
Lead sponsor: Sutphin Drugs; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jamaica, New York

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Princeton, New Jersey

Conditions: Candidiasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 99 Years
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • Torrance, California

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Amphotericin B; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Jose, California + 18 more

Conditions: Candidiasis
Interventions: micafungin, amphotericin B deoxycholate; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 48 Hours to 120 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Orange, California • New Brunswick, New Jersey • Durham, North Carolina + 2 more

Conditions: Candidemia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Birmingham, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more

Conditions: Invasive Candidiasis
Interventions: therapy duration; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more

Conditions: Candidiasis, Oral, Eating Disorders, HIV Infections, Speech Disorders
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Candida Infection, Oral Thrush, Early Childhood Caries
Interventions: Not listed
Lead sponsor: Temple University; Other
Eligibility: 9 Months to 15 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Candidiasis, Invasive, Candidemia, Mycoses
Interventions: Isavuconazole, Caspofungin, Voriconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more

Conditions: Candidiasis, Candidemia
Interventions: Micafungin, Caspofungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 62
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more

Search by objective public record fields.

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

Serial Therapeutic and Antifungal Monitoring Protocol

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

Bioavailability of Flucanazole

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

Funguria in Hospitalized Patients

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)

Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults

The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection

Oropharyngeal Candidiasis (OPC) and S-ECC

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia